The infection with SARS can be CoV-2 prevent?
A newly identified fully human monoclonal antibody prevents the Coronavirus SARS-CoV-2 to infect cells. This discovery is the first step in the development of a fully human antibody for the treatment or prevention of SARS-CoV-2-induced airway disease COVID-19.
In the current joint study of the Utrecht University, the Erasmus Medical Center and Harbour BioMed, it was found that a human monoclonal antibody prevents the spread of SARS-CoV-2, at least in laboratory tests on cell cultures. The results of the study were published in the English scientific journal “Nature Communications”.
Antibodies neutralized infection in cultured cells
The new research builds on studies of antibodies against the in the year 2002/2003, the occurrence of Coronavirus SARS-CoV. “With the help of this collection of SARS-CoV antibodies, we were able to identify an antibody that the infection with SARS-CoV neutralized 2 in cultured cells”, says Professor Berend-Jan Bosch of Utrecht University, in a press release.
What is the anti body can cause?
Such neutralizing antibodies has the potential to change the course of the infection of the infected body, to support the fight against the Virus or to protect a non-infected individual, which is exposed to the Virus, adds the expert.
Antibodies to protect against the new corona virus
The antibody binds to a domain, which occurs both in the case of SARS-CoV in SARS-CoV-2. This explains his ability to neutralize both viruses. This property of the antibody indicates that he could also have a potential for the relief of diseases which are caused in the future by the related corona virus, reports the researchers.
Results are the basis for new research
“This discovery provides a solid basis for further research work in order to characterize these antibodies and to start the development of a possible COVID-19-of treatment,” stresses the study’s author, Professor Frank Grosveld from the Erasmus Medical Center in Rotterdam.
The advantages of a human antibody
Conventional therapeutic antibodies are developed in other species, which means that additional steps are required to authorize and then to human. The used in this study antibody is fully human, making the development faster can move and the risk of immune-related side effects is reduced, explains the research team. However, to stay to provide a wide range of applications a lot of work to be able to clearly assess whether these antibodies COVID-can alleviate 19 the people actually. (as)